evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,234 questions · 3,357 findings · 396 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 803 · 23.9%GRADE not reported 270 · 8%Very low 757 · 22.5%Low 859 · 25.6%Moderate 486 · 14.5%High 182 · 5.4%

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Type 1 ROP or death before determination of ROP outcome using the adjudicated ROP outcome · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in type 1 ROP or death before determination of ROP outcome using the… compared with placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Type 1 ROP including adjudicated ROP outcome · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in type 1 ROP including adjudicated ROP outcome compared with placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

All‐cause mortality (outcome collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in all‐cause mortality (outcome collected through first event: death,… compared with placebo (moderate certainty).

1 finding from 1 review

Intervention not reported

Incidence of overt retinopathya,b · people with type 2 diabetes

The intervention showed no clear difference in incidence of overt retinopathya,b (moderate certainty).

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis

Alitretinoin showed no clear difference in proportion of participants achieving a 50% reduction in disease… compared with placebo (moderate certainty).

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis

Alitretinoin showed no clear difference in proportion of participants with adverse effects ‐ measured over 24… compared with placebo (moderate certainty).

1 finding from 1 review

Alteplase vs urokinase

Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy · adult parapneumonic effusions and empyema

Alteplase showed no clear difference in overall treatment failure, including mortality, thoracic surgery or… compared with urokinase (low certainty).

1 finding from 1 review